trending Market Intelligence /marketintelligence/en/news-insights/trending/Guc3aikZEJXaDu8JgrxS5w2 content esgSubNav
In This List

Sapporo Clinical Laboratory fiscal Q1 profit falls YOY

Blog

Using ESG Analysis to Support a Sustainable Future

Video

S&P Capital IQ Pro | Powered by Expert Insights

Blog

Q&A: Streamlining Analytics for TCFD Reporting

Blog

Evergrande and the wider impact: a sentiment analytics based perspective


Sapporo Clinical Laboratory fiscal Q1 profit falls YOY

Sapporo Clinical Laboratory Inc. said its normalized net income for the fiscal first quarter ended June 30 amounted to ¥14.92 per share, a decline of 61.5% from ¥38.80 per share in the year-earlier period.

Normalized net income, which excludes unusual gains or losses on a pre- and after-tax basis, was ¥59.4 million, a decrease of 61.5% from ¥154.4 million in the prior-year period.

The normalized profit margin fell to 1.4% from 3.8% in the year-earlier period.

Total revenue came to ¥4.13 billion, compared with ¥4.09 billion in the prior-year period, and total operating expenses rose on an annual basis to ¥4.04 billion from ¥3.85 billion.

Reported net income declined 63.7% year over year to ¥53.0 million, or ¥13.32 per share, from ¥146.0 million, or ¥36.69 per share.

As of Aug. 8, US$1 was equivalent to ¥101.85.